
Theriva Biologics, Inc.
100
Recent developments highlight Theriva Biologics’ clinical progress with VCN-01, strategic asset sales, and financial results showing narrowing losses. The company continues to advance clinical trials and manage its portfolio to focus on oncology therapeutics.
- Theriva Biologics reported third quarter 2026 results and completed the sale of the SYN-004 asset, signaling a strategic portfolio adjustment [N1].
- The company’s Q3 2026 loss narrowed compared to prior periods, reflecting some operational improvements [N2].
- Theriva Biologics sold its enzyme portfolio and shifted focus to the VCN-01 program, with positive market reaction [N3].
- The VIRAGE2 Phase 2a trial for VCN-01 in pancreatic cancer is underway, advancing clinical development [N4].
- Theriva dosed the first patient in the Phase 2a trial for pancreatic cancer with VCN-01, marking a clinical milestone [N5].
- Earlier, the company posted a narrower loss in Q1 2025 and reported positive Phase 2b results for VCN-01 in pancreatic ductal adenocarcinoma, supported by a $7.5 million public offering to advance cancer therapeutics [N6][N7][N8].
Theriva Biologics, Inc. operates as a clinical-stage biopharmaceutical company specializing in oncolytic virus therapies targeting various cancers. Its lead product candidate, VCN-01, is in mid-to-late stage clinical trials for pancreatic ductal adenocarcinoma. The company has no commercial products and has historically generated minimal revenues, focusing on research, development, and clinical evaluation. It has completed enrollment in key trials and secured regulatory designations to facilitate development. The company has recently divested non-core assets to prioritize VCN-01. Financially, Theriva Biologics has experienced recurring losses and maintains liquidity sufficient to support operations into early 2027, but requires additional capital to continue development and commercialization efforts. The company’s operations include multiple subsidiaries and licensing arrangements.
Theriva Biologics, Inc. is a clinical-stage biopharmaceutical company focused on developing oncolytic virus therapies for cancer, primarily its lead candidate VCN-01. The company has no approved products and has incurred significant operating losses, with a net loss of $23.7 million as of December 31, 2025. As of September 30, 2026, it held $8.47 million in cash and equivalents with a current ratio of 1.21, sufficient to fund operations into early 2027 under current plans. The company has shifted strategic focus by selling its enzyme portfolio and licensing SYN-020, concentrating resources on VCN-01 development. Clinical trials including the VIRAGE Phase 2b and VIRAGE2 Phase 2a trials for pancreatic cancer are underway. The company faces material uncertainties regarding its ability to continue as a going concern without additional capital and expects to incur further losses while advancing clinical programs. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Theriva Biologics has advanced its lead candidate VCN-01 through multiple clinical trial phases, including completion of enrollment in the VIRAGE Phase 2b trial and initiation of the VIRAGE2 Phase 2a trial to refine dosing. The company has secured regulatory designations that may facilitate development and potential approval pathways. Recent strategic moves such as selling its enzyme portfolio and licensing SYN-020 indicate a focused allocation of resources toward oncology therapeutics. The company has also raised capital through public offerings to support its clinical programs. These developments demonstrate active execution on its clinical and strategic plans.
Theriva Biologics faces significant risks including recurring operating losses, a net capital deficiency, and material uncertainties about its ability to continue as a going concern without additional financing. The company has no approved products or revenues and depends heavily on raising capital to fund ongoing and future clinical trials, regulatory approvals, and commercialization efforts. Failure to secure adequate funding could force delays, reductions, or cessation of development programs. The company’s contingent milestone payments and potential dilution from equity offerings add financial risk. Additionally, the inherent uncertainties of clinical development and regulatory approval pose execution risks.
Theriva Biologics’ moat is primarily based on its proprietary oncolytic virus technology platform and its lead candidate VCN-01, which has obtained Fast Track and Rare Disease designations. The company’s clinical trial progress and regulatory designations provide some competitive differentiation in the oncology biopharmaceutical space. However, as a clinical-stage company without approved products or revenues, its moat is limited by the inherent risks of drug development, regulatory approval, and capital requirements. The company’s ability to maintain intellectual property rights and advance clinical programs will be critical to sustaining any competitive advantage.
• Capital and Liquidity Risk: The company has recurring losses and a net capital deficiency, with cash sufficient to fund operations only into early 2027. Additional capital is required to continue clinical trials and operations, and failure to obtain funding could materially impair business continuity.
• Clinical and Regulatory Risk: Theriva Biologics’ product candidates are in clinical development stages and require successful trial outcomes and regulatory approvals. Delays or failures in these processes could adversely affect the company’s prospects.
• Operational Risk: The company has identified and remediated material weaknesses in internal controls over financial reporting but cannot guarantee future effectiveness, which could impact financial reporting and investor confidence.
• Strategic Risk: The company’s focus on VCN-01 and divestiture of other assets concentrates risk on a single product candidate. Dependence on partnerships and licensing arrangements introduces additional execution risks.
Business trends: Continued clinical development of VCN-01 with focus on pancreatic cancer trials and strategic portfolio refinement.
Execution milestones: Completion of VIRAGE Phase 2b enrollment, initiation of VIRAGE2 Phase 2a trial, and asset sales to concentrate resources.
Key risks: Dependence on raising additional capital, clinical and regulatory uncertainties, and operational challenges related to financial controls and execution.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Theriva Biologics, Inc. is a clinical-stage biopharmaceutical company focused on developing oncolytic viruses (OVs) for cancer treatment, with its lead product candidate VCN-01 (zabilugene almadenorepvec).
- The company has no products approved for commercial sale and has not generated significant revenues to date, focusing primarily on research and development and clinical trials.
- Theriva Biologics completed enrollment in the VIRAGE Phase 2b trial of VCN-01 for metastatic pancreatic cancer and has secured Fast Track and Rare Disease designations for this candidate.
- The company has advanced the VCN-01 program with the VIRAGE2 Phase 2a trial underway to refine dosing in pancreatic cancer.
- Theriva dosed the first patient in the Phase 2a trial for pancreatic cancer with VCN-01.
- Theriva Biologics sold its enzyme portfolio and shifted focus to VCN-01, indicating a strategic prioritization of its lead oncology candidate.
- The company reported a narrower net loss in Q1 2026 and a drop in Q3 2026 loss, reflecting some improvement in operating results.
- Theriva Biologics completed a $7.5 million public offering in 2025 to advance cancer therapeutics development.
- As of September 30, 2026, the company had $8.47 million in cash and cash equivalents and a current ratio of 1.21, indicating liquidity to fund operations into early 2027.
- The company’s net income was negative $23.7 million as of December 31, 2025, reflecting ongoing operating losses.
- Theriva Biologics has material uncertainties regarding its ability to continue as a going concern without additional capital, with cash sufficient to fund operations only into the first quarter of 2027 under current plans.
- The company expects to incur additional operating losses and requires further capital to continue clinical trials, regulatory approvals, and commercialization efforts.
- Theriva Biologics has agreed to pay contingent consideration up to $70.2 million related to acquisition milestones, with $7.3 million paid and $5.0 million deferred pending discussions, which could impact liquidity.
- The company’s ability to raise capital is critical to its operations and may involve dilution or restrictive covenants.
- Theriva Biologics has identified and remediated material weaknesses in internal controls over financial reporting but cannot guarantee future effectiveness.
- The company’s operations include subsidiaries such as VCN Biosciences, Pipex Therapeutics, and others.
- Theriva Biologics licensed SYN-020 to Rasayana for multiple indications and sold the SYN-004 asset.
- The company’s recent news includes detailed reporting on clinical trial progress, financial results, asset sales, and strategic focus shifts.
- Theriva Biologics had 45,892,668 shares of common stock outstanding as of November 10, 2026.
Generated 2026-11-15
- S1 | 2026-03-12 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-13 | www.nasdaq.com | Theriva Biologics, Inc. Reports Third Quarter 2026 Results and SYN-004 Asset Sale | https://www.nasdaq.com/articles/theriva-biologics-inc-reports-third-quarter-2026-results-and-syn-004-asset-sale
- N2 | 2026-11-12 | www.nasdaq.com | Theriva Biologics, Inc. Q3 Loss Drops | https://www.nasdaq.com/articles/theriva-biologics-inc-q3-loss-drops
- N3 | 2026-11-03 | www.nasdaq.com | Theriva Biologics Sells Enzyme Portfolio; Shifts Focus To VCN-01; Stock Up | https://www.nasdaq.com/articles/theriva-biologics-sells-enzyme-portfolio-shifts-focus-vcn-01-stock
- N4 | 2026-08-11 | www.nasdaq.com | Theriva Biologics Advances VCN-01 Program; VIRAGE2 Trial Underway In Pancreatic Cancer | https://www.nasdaq.com/articles/theriva-biologics-advances-vcn-01-program-virage2-trial-underway-pancreatic-cancer
- N5 | 2026-08-07 | www.nasdaq.com | Theriva Doses First Patient With VCN-01 In Phase 2a Trial For Pancreatic Cancer | https://www.nasdaq.com/articles/theriva-doses-first-patient-vcn-01-phase-2a-trial-pancreatic-cancer
- N6 | 2025-05-14 | www.nasdaq.com | Theriva Biologics Posts Narrower Loss In Q1 | https://www.nasdaq.com/articles/theriva-biologics-posts-narrower-loss-q1
- N7 | 2025-05-14 | www.nasdaq.com | Theriva Biologics Reports Positive Phase 2b Results for VCN-01 in Pancreatic Ductal Adenocarcinoma and Raises $7.5 Million in Public Offering | https://www.nasdaq.com/articles/theriva-biologics-reports-positive-phase-2b-results-vcn-01-pancreatic-ductal
- N8 | 2025-05-08 | www.nasdaq.com | Theriva Biologics Closes $7.5 Million Public Offering to Advance Cancer Therapeutics | https://www.nasdaq.com/articles/theriva-biologics-closes-75-million-public-offering-advance-cancer-therapeutics
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


